Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma.
Cancers (Basel)
; 13(5)2021 Feb 24.
Article
in En
| MEDLINE
| ID: mdl-33668183
Full text:
1
Database:
MEDLINE
Type of study:
Diagnostic_studies
/
Prognostic_studies
Language:
En
Journal:
Cancers (Basel)
Year:
2021
Type:
Article
Affiliation country:
United kingdom